Company news
HanchorBio Inc. news in 2026
HanchorBio Inc.'s news releases, calls and decks from 2026, newest first.
HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy
October 5, 2026
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
September 9, 2026
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
July 8, 2026